Here's your US review and approval news in brief for the week: Two more novel drugs have cleared the Food and Drug Administration's review hurdle, with Epizyme Inc.'s Tazverik (tazemetostat) and Horizon Therapeutics PLC's Tepezza (teprotumumab-trbw) becoming the most recent to get the agency's green light.
GlaxoSmithKline PLC is looking to make a splash with its multiple myeloma candidate belantamab mafodotin, which earned a priority review and the inside track to